Experimental treatment of equine sarcoid using a xanthate compound and recombinant human tumour necrosis factor alpha.
A xanthate compound with antiviral and antitumoural activities, tricyclodecan-9-yl-xanthogenate (D609) in combination with the potassium salt of the lauric acid (KC12) and, in a further investigation, the above-mentioned substances together with recombinant human TNF alpha (rh-TNF alpha), were tested on equine sarcoid tumours for therapeutic efficacy. A pilot investigation on 5 healthy horses showed that the compounds were well-tolerated; apart from a local, temporary oedema at the injection site, no other clinical symptoms were observed after subcutaneous administration of volumes from 0.1 to 10 ml per injection. The tested concentrations of D609 and KC12 (5 mg/ml solution) and of rh-TNF alpha (50 micrograms/ml) were used for the treatment experiments. The repeated injections of the compounds to 11 sarcoid affected horses were also well-tolerated, except by one horse. In this case the treatment had to be interrupted after two injections because of severe reaction, i.e. fever and lameness due to oedemas. Five horses (n = 6 sarcoids) were treated by local, subcutaneous injection of D609 and KC12 under the tumour at intervals of 3 weeks. On one periocular sarcoid the compounds were applied as an ointment. After a follow-up period of 18 months, 5 tumours did completely regress and one remained unchanged. The periocular tumour showed a reduction in size. Five horses (n = 9 sarcoids) were then treated with a combination of D609, KC12 and rh-TNF alpha.(ABSTRACT TRUNCATED AT 250 WORDS)
Otten
N
N
Klinik für Nutztiere und Pferde, Bern, Switzerland.
Marti
E
E
Söderström
C
C
Amtmann
E
E
Burger
D
D
Gerber
H
H
Lazary
S
S
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006734:Horse Diseases / Q000188:drug therapy*; D006736:Horses; D006801:Humans; D007850:Lauric Acids / Q000627:therapeutic use; D008297:Male; D009636:Norbornanes; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D013859:Thiocarbamates; D013871:Thiones / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D007850:Lauric Acids; D009636:Norbornanes; D011994:Recombinant Proteins; D013859:Thiocarbamates; D013871:Thiones; D014409:Tumor Necrosis Factor-alpha; C030358:lauric acid; C046498:tricyclodecane-9-yl-xanthogenate